MedPath

Effect of Fluticasone Furoate on Methacholine Challenge

Phase 4
Completed
Conditions
Asthma
Interventions
Other: Matching placebo
Registration Number
NCT03898466
Lead Sponsor
University of Saskatchewan
Brief Summary

The study will determine the effect of inhaled fluticasone furoate on airway responsiveness to methacholine in mild asthmatics.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
14
Inclusion Criteria
  • forced expiratory volume in one second (FEV1) greater than or equal to 65% predicted
  • methacholine PD20 less than or equal to 400mcg
  • no allergen exposure (if atopic) or respiratory infection for at least 4 weeks prior to study start
Exclusion Criteria
  • regular use of inhaled corticosteroid within 4 weeks of study start
  • poorly controlled asthma
  • current smoker or ex smoker with greater than 10 pack year history
  • pregnancy or breast-feeding
  • health concern/condition that would preclude participation for safety reasons

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Fluticasone FuroateFluticasone furoateDaily inhalation of 100mcg fluticasone furoate for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours. The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints
Matching PlaceboMatching placeboDaily inhalation of inactive placebo comparator for 7 days Response to methacholine induced bronchoconstriction will be assessed on Day 1 before first inhalation of study treatment (baseline) and again at 24, 72 and 168 hours. The change in airway responsiveness to methacholine will be determined as a dose shift in methacholine PD20 from baseline to each of the three timepoints
Primary Outcome Measures
NameTimeMethod
Methacholine provocation dose causing a 20% fall in FEV1 (PD20)24 hours post dose, 72 hours post dose and 168 hours post dose

Change from baseline in airway response to inhaled methacholine following daily dosing with fluticasone furoate or placebo

Secondary Outcome Measures
NameTimeMethod
Fractional exhaled nitric oxide (FeNO)168 hours

Change from baseline on levels of fractional exhaled nitric oxide

Sputum eosinophilsBaseline

Assessment of induced sputum differential cell counts

Trial Locations

Locations (1)

Asthma Research Lab University of Saskatchewan Room 346 Ellis Hall

🇨🇦

Saskatoon, Saskatchewan, Canada

© Copyright 2025. All Rights Reserved by MedPath